Trial Schema: Randomized Phase II Study of CHO(E)P vs. CC-486-CHO(E)P vs. Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas.

Phase II Safety Check. The randomized study will have a safety check (the first 12 patients enrolled to each treatment arm) before expanding to the full phase II trial. In arms A, B, and C, the safety check will include six patients with CHOP chemotherapy and six with CHOEP chemotherapy.